Novel functions for NFκB: Inhibition of bone formation

Nature Reviews Rheumatology

Volumn 6, Issue 10, 2010, Pages 607-611

  Krum, Susan A ^a   Chang, Jia ^b   Miranda Carboni, Gustavo ^a   Wang, Cun Yu ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA SCHOOL OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DENOSUMAB; ESTROGEN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOPROTEGERIN; PROTEIN INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FRA 1;

ARTHRITIS; BONE DISEASE; CELL FUNCTION; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; MOLECULAR INTERACTION; MULTIPLE MYELOMA; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; ESTRADIOL; GENE EXPRESSION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, KNOCKOUT; NF-KAPPA B; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OVARIECTOMY; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957587105     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.133     Document Type: Review

References (48)

1. Ghosh, S. & Karin, M. Missing pieces in the NF-κB puzzle. Cell 109 (Suppl.), S81-S96 (2002).
2. Granic, I., Dolga, A. M., Nijholt, I. M., van Dijk, G. & Eisel, U. L. Inflammation and NF-κB in Alzheimer's disease and diabetes. J. Alzheimers Dis. 16, 809-821 (2009).
3. Geusens, p. emerging treatments for postmenopausal osteoporosis-focus on denosumab. Clin. Interv. Aging 4, 241-250 (2009).
4. Jimi, E. & Ghosh, S. role of nuclear factor-κB in the immune system and bone. Immunol. Rev. 208, 80-87 (2005).
5. Lee, Z. H. & Kim, H. H. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem. Biophys. Res. Commun. 305, 211-214 (2003).
6. Soysa, N. S. & Alles, N. NF-κB functions in osteoclasts. Biochem. Biophys. Res. Commun. 378, 1-5 (2009).
7. Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337-342 (2003).
8. Yamashita, T. et al. NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (rANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J. Biol. Chem. 282, 18245-18253 (2007).
9. Kim, J. H. et al. The mechanism of osteoclast differentiation induced by IL-1. J. Immunol. 183, 1862-1870 (2009).
10. Jimi, E. et al. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents nflammatory bone destruction in vivo. Nat Med. 10, 617-624 (2004).
11. Vaira, S. et al. RelB is the NF-κB subunit downstream of NIK responsible for osteoclast differentiation. Proc. Natl Acad. Sci. USA 105, 3897-3902 (2008).
12. Iotsova, V. et al. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat. Med. 3, 1285-1289 (1997).
13. Franzoso, G. et al. requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11, 3482-3496 (1997).
14. Ruocco, M. G. et al. IκB kinase (IKK)β, but not KKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 201, 1677-1687 (2005).
15. Takeda, K. et al. Limb and skin abnormalities in mice lacking IKKα. Science 284, 313-316 (1999).
16. Sil, A. K., Maeda, S., Sano, Y., Roop, D. R. & Karin, M. IκB kinase-α acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature 428, 660-664 (2004).
17. De Smaele, E. et al. Induction of gadd45ß by NF-κB downregulates pro-apoptotic JNK signalling. Nature 414, 308-313 (2001).
18. Tang, G. et al. Inhibition of JNK activation through NF-κB target genes. Nature 414, 313-317 (2001).
19. Vaira, S. et al. relA/p65 promotes osteoclast differentiation by blocking a rANKL-induced apoptotic JNK pathway in mice. J. Clin. Invest 118, 2088-2097 (2008).
20. Chang, J. et al. Inhibition of osteoblastic bone formation by nuclear factor-κB. Nat Med. 15, 682-689 (2009).
21. Eferl, R. et al. The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J. 23, 2789-2799 (2004).
22. Julien, M. et al. phosphate-dependent regulation of MGp in osteoblasts: role of erK1/2 and Fra-1. J. Bone Miner. Res. 24, 1856-1868 (2009).
23. Pfeilschifter, J., Köditz, R., Pfohl, M. & Schatz, H. changes in proinflammatory cytokine activity after menopause. Endocr. Rev. 23, 90-119 (2002).
24. Weitzmann, M. N. & Pacifici, R. estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest. 116, 1186-1194 (2006).
25. Gilbert, L. et al. expression of the osteoblast differentiation factor rUNX2 (cbfa1/AML3/ pebp2αA) is inhibited by tumor necrosis factor-alpha. J. Biol. Chem. 277, 2695-2701 (2002).
26. Kaneki, H. et al. Tumor necrosis factor promotes runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J. Biol. Chem. 281, 4326-4333 (2006).
27. Lu, X., Gilbert, L., He, X., rubin, J. & Nanes, M. S. Transcriptional regulation of the osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NFκB pathways. J. Biol. Chem. 281, 6297-6306 (2006).
28. Ding, J. et al. TNF-α and IL-1 β inhibit rUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. Life Sci. 84, 499-504 (2009).
29. Gilbert, L. C., Rubin, J. & Nanes, M. S. The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis. Am. J. Physiol. Endocrinol. Metab. 288, e1011-e1018 (2005).
30. Krum, S. A. & Brown, M. Unraveling estrogen action in osteoporosis. Cell Cycle 7, 1348-1352 (2008).
31. Krum, S. A. et al. estrogen protects bone by nducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J. 27, 535-545 (2008).
32. Kalaitzidis, D. & Gilmore, T. D. Transcription factor cross-talk: the estrogen receptor and NF-κB. Trends Endocrinol. Metab. 16, 46-52 (2005).
33. Cvoro, A. et al. Distinct roles of unliganded and iganded estrogen receptors in transcriptional repression. Mol. Cell 21, 555-564 (2006).
34. Li, Y. et al. endogenous TNFα lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-κB. J. Bone Miner. Res. 22, 646-655 (2007).
35. Keffer, J. et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025-4031 (1991).
36. high osteoclast precursors in tumor necrosis factor α-transgenic mice. Arthritis Rheum. 50, 265-276 (2004).
37. Kitazawa, R., Kimble, R. B., Vannice, J. L., Kung, V. T. & Pacifici, R. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J. Clin. Invest. 94, 2397-2406 (1994).
38. Jilka, R. L. et al. Increased osteoclast development after estrogen loss: mediation by nterleukin-6. Science 257, 88-91 (1992).
39. Weitzmann, M. N., Roggia, C., Toraldo, G., Weitzmann, L. & Pacifici, R. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J. Clin. Invest. 110, 1643-1650 (2002).
40. Kimble, RR. B. et al. Simultaneous block of nterleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology 136, 3054-3061 (1995).
41. Raisz, L. G. pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 115, 3318-3325 (2005).
42. Deal, C. Future therapeutic targets in osteoporosis. Curr. Opin. Rheumatol. 21, 380-385 (2009).
43. Mukherjee, S. et al. pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J. Clin. Invest. 118, 491-504 (2008).
44. Chen, Z. J. Ubiquitin signalling in the NF-κB pathway. Nat Cell Biol. 7, 758-765 (2005).
45. Wang, C. Y., Mayo, M. W. & Baldwin, A. S. Jr. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274, 784-787 (1996).
46. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V. & Baldwin, A. S. Jr. NF-κB antiapoptosis: induction of TrAF1 and TrAF2 and c-IAp1 and c-IAp2 to suppress caspase-8 activation. Science 281, 1680-1683 (1998).
47. Kousteni, S. et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104, 719-730 (2001).
48. Chen, S. et al. Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor κB-ndependent bone morphogenetic protein/ Smad signaling. J. Biol. Chem. 276, 39259-39263 (2001).